Evotec AG has entered into a three-year drug discovery collaboration with UCB to identify small molecule modulators of biological targets selected by UCB, in CNS disorders. Financial details were not disclosed. Evotec will apply its integrated drug discovery expertise and technologies to identify small molecules against the selected targets to be further optimized through lead optimization to a preclinical candidate. Evotec will receive fixed research funding and early stage discovery, preclini...